The role of tumor lymphangiogenesis in metastatic spread

FASEB Journal

Volumn 16, Issue 9, 2002, Pages 922-934

  Stacker, Steven A ^a   Baldwin, Megan E ^a   Achen, Marc G ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Metastasis; VEGF receptors; VEGF C; VEGF D

Indexed keywords

UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL MODEL; CANCER MORTALITY; CANCER STAGING; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; METASTASIS; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE;

ANIMALS; BIOLOGICAL MARKERS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM; HUMANS; LYMPHATIC METASTASIS; LYMPHATIC SYSTEM; LYMPHOKINES; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA;

EID: 0036310316     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.01-0945rev     Document Type: Review

References (150)

1. Cancer statistics, 2001
2. Making headway against cancer
3. Molecular biology of cancer: Invasion and metastasis
4. How cancer spreads
5. Electron microscopic observations on lymphatic capillaries and the structural components of the connective tissue-lymph interface
6. The structure of normal small lymphatics
7. Lymphatic function, lymphangiogenesis, and cancer metastasis
8. Angiogenic factors
9. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
10. The growth of malignant disease in man and the lower animals with special reference to the vascular system
11. Vascularization of the Brown-Pearce rabbi epithelioma transplant as seen in the transparent ear chamber
12. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants
13. Tumor angiogenesis: Transfilter diffusion studies in the hamster by transparent chamber technique
14. Choriocarcinoma: Transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy
15. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
16. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
17. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
18. Lymphangiogenesis in malignant tumours: Does it occur?
19. Lymphatic vessels as targets of tumor therapy
20. The classification of cancer of the rectum
21. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update
22. Lymphangiogenesis and tumor metastasis: More questions than answers
23. Lymphangiogenesis and tumor metastasis: Myth or reality?
24. Markers for the lymphatic endothelium: In search of the holy grail?
25. Fine structure of the lymphatic capillary and the adjoining connective tissue area
26. Lymphangiogenesis and lymphangiodysplasia: From molecular to clinical lymphology
27. Structure and function of lymphatics
28. Structure, function, and molecular control of the skin lymphatic system
29. Some observations on the structure and functions of lymphatics: Their behavior in local edema
30. Lymphangiogenesis: Mechanisms, significance and clinical implications
31. VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
32. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
33. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk-1) and VEGF receptor 3 (Flt-4)
34. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
35. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
36. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice
37. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
38. Mechanisms of angiogenesis
39. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
40. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3
41. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily
42. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors
43. Identification of lymph and blood capillaries by immunohistochemical staining for various basement membrane components
44. Immunohistochemical differentiation between lymphatic vessels and blood vessels-use of anti-basement membrane antibodies and anti-factor VIII-related antigen
45. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against vascular endothelial growth factor receptor-3
46. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
47. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development
48. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors
49. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing
50. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
51. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium
52. LYVE-1, the lymphatic system and tumor lymphangiogenesis
53. LYVE-1 is not restricted to the lymph vessels: Expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis
54. Proxl function is required for the development of the murine lymphatic system
55. Hepatocyte migration during liver development requires Prox1?
56. Proxl function is crucial for mouse lens-fibre elongation
57. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Podoplanin as a specific marker for lymphatic endothelium
58. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells
59. Desmoplakin as a specific marker of lymphatic vessels
60. A novel vascular endothelial growth factor. VEGF-C, is a ligand for the Flt-4(VEGFR-3)and KDR(VEGFR-2)receptor tyrosine kinases
61. The vascular endothelial growth factor family; proteins which guide the development of the vasculature
62. Growth factors regulating lymphatic vessels
63. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
64. The vascular endothelial growth factor family: Signaling for vascular development
65. A structural superfamily of growth factors containing a cystine knot motif
66. Proteolytic processing regulates receptor specificity and activity of VEGF-C
67. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers
68. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3
69. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities
70. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability
71. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4
72. Vascular endothelial growth factor C induces angiogenesis in vivo
73. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro
74. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
75. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C
76. Mapping of the gene for vascular endothelial growth factor-D in mouse and man to the X chromosome
77. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family
78. In fibroblasts Vegf-D expression is induced by cell-cell contact mediated by cadherin-11
79. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme
80. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
81. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase
82. Vascular endothelial growth factor receptor-3
83. Sentinel lymph node biopsy in melanoma of the head and neck
84. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
85. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma
86. Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation
87. The regeneration of the lymphatics
88. Enhanced expression of vascular endothelial growth factor in metastatic melanoma
89. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
90. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
91. Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients
92. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis
93. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer
94. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features
95. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer
96. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues
97. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma
98. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer
99. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
100. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer
101. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis
102. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth
103. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma
104. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
105. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema
106. Adenoviral expression of vascular endothelial growth factor-c induces lymphangiogenesis in the skin
107. Monoclonal antibodies to vascular endothelial growth factor-D block interactions with both VEGF receptor-2 and VEGF receptor-3
108. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis
109. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor
110. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
111. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
112. Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane
113. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma
114. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells
115. Lymphedema: Anatomy, physiology and pathogenesis
116. Current puzzles presented by postmastectomy oedema (breast cancer related lymphoedema)
117. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues
118. Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma
119. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer
120. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium
121. A model for gene therapy of human hereditary lymphedema
122. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
123. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines
124. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors
125. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III
126. Proxl is a marker of ectodermal placodes, endodermal compartments, lymphatic endothelium and lymphangioblasts
127. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis
128. Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells
129. Cerium-induced light-microscopic demonstration of 5′-nucleotidase activity in the lymphatic capillaries of the proximal oesophagus of the rat
130. VEGFR-3 in adult angiogenesis
131. Vascular endothelial growth factor receptor-3 (VEGFR-3): A marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas
132. flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors
133. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium
134. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis
135. Monoclonal antibody PAL-E specific for endothelium
136. Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31. CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ
137. Endothelial cell synthesis of von Willebrand antigen II, von Willebrand factor, and von Willebrand factor/von Willebrand antigen II complex
138. Molecular architecture of basement membranes
139. Basement membranes: Molecular organization and function in development and disease
140. Use of anti-basement membrane antibodies to distinguish blood vessel capillaries from lymphatic capillaries
141. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter
142. The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man
143. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma
144. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis
145. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression
146. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas
147. Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice